144 related articles for article (PubMed ID: 22060549)
1. Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.
Waud WR; Gilbert KS; Parker WB; Secrist JA
Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):826-38. PubMed ID: 22060549
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.
Waud WR; Parker WB; Gilbert KS; Secrist JA
Nucleosides Nucleotides Nucleic Acids; 2012; 31(1):14-27. PubMed ID: 22257207
[TBL] [Abstract][Full Text] [Related]
3. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.
Yamanishi M; Narazaki H; Asano T
Exp Hematol; 2015 Mar; 43(3):207-14. PubMed ID: 25461250
[TBL] [Abstract][Full Text] [Related]
4. Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.
Waud WR; Gilbert KS; Secrist JA
Cancer Chemother Pharmacol; 2011 Aug; 68(2):399-403. PubMed ID: 21069340
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
7. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
8. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Ahluwalia GS; Cohen MB; Kang GJ; Arnold ST; McMahon JB; Dalal M; Wilson YA; Cooney DA; Balzarini J; Johns DG
Cancer Res; 1986 Sep; 46(9):4479-85. PubMed ID: 2425954
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of anti-cancer action and pharmacology of clofarabine.
Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
11. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
12. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
[TBL] [Abstract][Full Text] [Related]
14. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
15. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Lech-Maranda E; Korycka A; Robak T
Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity.
Majda K; Lubecka K; Kaufman-Szymczyk A; Fabianowska-Majewska K
Acta Pol Pharm; 2011; 68(4):459-66. PubMed ID: 21796927
[TBL] [Abstract][Full Text] [Related]
19. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
20. The role of clofarabine in acute myeloid leukemia.
Ghanem H; Kantarjian H; Ohanian M; Jabbour E
Leuk Lymphoma; 2013 Apr; 54(4):688-98. PubMed ID: 22957815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
